摘要
目的探讨达格列净联合厄贝沙坦治疗糖尿病肾病的治疗效果。方法选取2020年1月—2021年1月淄博市中心医院收治的100例2型糖尿病肾病患者为研究对象,随机分为对照组和观察组,各50例。对照组采用厄贝沙坦治疗,观察组采用达格列净联合厄贝沙坦治疗。对比两组患者治疗效果、治疗前后血糖指标、肾功能指标及不良反应发生情况。结果观察组治疗总有效率为92.00%高于对照组的72.00%,差异有统计学意义(P<0.05)。治疗后,观察组FPG、2 hPG、HbA1c比对照组更低,差异有统计学意义(P<0.05)。治疗后,观察组血肌酐、尿蛋白排泄率、24 h尿蛋白定量显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率为8.00%低于对照组的26.00%,差异有统计学意义(P<0.05)。结论对2型糖尿病肾病患者使用达格列净联合厄贝沙坦治疗可显著提高治疗有效率,并能明显改善患者血糖及肾功能等指标,且安全可靠。
Objective To investigate the therapeutic effect of dagliazine combined with irbesartan in the treatment of diabetic nephropathy.Methods 100 patients with type 2 diabetic nephropathy admitted to Zibo Central Hospital from January 2020 to January 2021 were selected as the study objects,and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with irbesartan,and the observation group was treated with dagliazine combined with irbesartan.The therapeutic effect,blood glucose index,renal function index and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.00%,which was higher than that of the control group(72.00%),and the difference was statistically significant(P<0.05).After treatment,FPG,2 hPG and HbA1c in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,serum creatinine,urinary protein excretion rate and 24 h urinary protein quantity in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group(8.00%)was lower than that in the control group(26.00%),and the difference was statistically significant(P<0.05).Conclusion In the treatment of type 2 diabetic nephropathy patients,dagliazine combined with irbesartan can significantly improve the effective rate,blood glucose and renal function,and other indicators,and is safe and reliable.
作者
刘昕峰
汪红
LIU Xinfeng;WANG Hong(Department of Pharmacy,Zibo Central Hospital,Zibo,Shandong Province,255022 China)
出处
《糖尿病新世界》
2023年第8期175-177,181,共4页
Diabetes New World Magazine
关键词
糖尿病肾病
达格列净
厄贝沙坦
肾功能
Diabetic nephropathy
Dapagliflozin
Irbesartan
Renal function
